Medtronic plc
Global leader in medical technology, services, and solutions with over 95,000 employees serving physicians, hospitals, and patients in more than 150 countries.
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 9.2/100 with low retention risk and high switching costs.
Growth appears mixed from +6.9% YoY revenue growth.
Forward P/E of 13.2x versus +6.9% growth gives a 1.9x multiple-to-growth read.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Retention and AI disruption risks are low; valuation is not flagged expensive.
Fundamentals from finnhub as of 2026-05-17; ownership confirmation is not available here.
This is the clearest available company growth signal in the current data.
Beginner valuation check
Data pending from FMP or Finnhub.
Negative price performance shows recent market sentiment, not a full investment thesis.
Forward P/E around 13.2x means investors pay about $13.2 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.
A P/E around 21.2x means investors pay about $21.2 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Medtronic makes medical devices like pacemakers, insulin pumps, and surgical robots that doctors use to help sick people feel better.
Global leader in medical technology, services, and solutions with over 95,000 employees serving physicians, hospitals, and patients in more than 150 countries.
Medtronic plc makes money through Cardiovascular (~33% of revenue), Neuroscience (~24% of revenue), Medical Surgical (~25% of revenue), and Diabetes (~6% of revenue).
Clinical specialists embedded in hospitals create 'stickiness' - customers rely on MDT expertise daily
Medtronic plc can disappoint if execution, competition, valuation, or demand cycles weaken growth, margins, customer retention, or investor confidence.
Medtronic plc is like a specialized business engine: investors want to know whether cardiovascular can keep producing durable cash flow.
You are basically betting that Medtronic plc can keep turning cardiovascular into durable value while managing execution, competition, valuation, or demand cycles.
A 0-100 shortcut for how defensible the business looks in this company brief. Medtronic plc is scored at 9.2.
How painful it is for customers to leave. this company brief rates Medtronic plc as high.
Whether existing customers tend to spend more or less over time. The company brief model uses 108%.
The main pieces of the company here are Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.
Price divided by earnings. It is a quick valuation check, but it can mislead when earnings are temporarily high, low, or negative.
A quarterly filing that shows what many large institutional investors owned at quarter end.
The first four questions
MDT’s hospital embeddedness matters because clinical specialists, surgeon training, and regulatory barriers make switching painful; that supports the cardiovascular-led device franchise as a durable operating engine.
MDT can struggle if execution slips, competition intensifies, or demand cycles weaken growth and investor confidence; recent price weakness also shows the market is not currently rewarding the name for momentum.
Forward P/E (13.2x)
Next earnings date unavailable from configured sources.
Bull / Neutral / Bear
Medtronic keeps converting its installed base into durable cash flow, while the current forward multiple stays tied to modest growth rather than a big re-rating.
Forward P/E around 13.2x remains broadly aligned with the company’s growth and device-quality profile.
Cardiovascular and the other device businesses keep benefiting from hospital embeddedness, while revenue growth stays near the current 6.9% pace or improves.
Revenue growth remains positive and the installed-base moat continues to support recurring procedures, service, and replacement demand.
Medtronic keeps converting its installed base into durable cash flow, while the current forward multiple stays tied to modest growth rather than a big re-rating.
Forward P/E around 13.2x remains broadly aligned with the company’s growth and device-quality profile.
If execution, competition, or demand-cycle pressure hurts growth in cardiovascular or other core lines, the market may keep discounting the stock despite the moat.
Growth weakens, sentiment stays soft, or ownership flow remains unavailable so there is no 13F support to offset the operating concerns.
Beginner checklist
Needs earnings calendar data from a provider.
This is the clearest available company growth signal in the current data.
Margin trend needs company financial statement data; do not infer it from price movement.
Use this as a valuation anchor, then compare it with growth and the durability of the device franchise.
No SEC-backed ownership rows are available for this ticker yet.
Needs insider transaction data from a provider.
For MDT, start with whether cardiovascular remains the core durable engine behind the broader medical-device portfolio.
Medtronic plc is exposure to medical devices operating model with high switching costs and 108% net revenue retention.
Clinical specialists embedded in hospitals create 'stickiness' - customers rely on MDT expertise daily
The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.
Pro access unlocks the workflow simulator for this company brief.
Simulator coverage pending
This ticker has a company brief, but richer workflow modules have not been built yet.
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- Clinical specialists embedded in hospitals create 'stickiness' - customers rely on MDT expertise daily
- FDA regulatory moats: Each device approval takes 3-7 years and $50M+, creating massive barriers
- Surgeon training lock-in: Doctors spend years mastering MDT devices, reluctant to switch
- Mission-critical nature means price sensitivity is low - hospitals pay premium for reliability
- Integration complexity: MDT systems deeply embedded in hospital workflows and EMR systems
- AI opportunity: Patient data from 12M+ implanted devices creates unique dataset for ML models